Profile
Mark Rigby worked as Vice President-Clinical Development at Provention Bio, Inc. from 2018 to 2020.
He received an undergraduate degree from Duke University and a doctorate degree from the University of Massachusetts.
Former positions of Mark Rigby
| Companies | Position | End |
|---|---|---|
| PROVENTION BIO, INC. | Corporate Officer/Principal | 2019-12-31 |
Training of Mark Rigby
| Duke University | Undergraduate Degree |
| University of Massachusetts | Doctorate Degree |
Experiences
Positions held
Connections
1st degree connections
1st degree companies
Male
Female
Members of the board
Executives
Linked companies
| Private companies | 1 |
|---|---|
Provention Bio, Inc.
 Provention Bio, Inc. Pharmaceuticals: MajorHealth Technology Provention Bio, Inc. is a clinical-stage biopharmaceutical company, which engages in the development and commercialization of novel therapeutics and solutions. Its products include PRV-031 for the interception of type 1 diabetes (T1D), PRV-015 for the treatment of gluten-free diet non-responding celiac disease, PRV-6527 for Crohn’s disease, PRV-3279 for the treatment of lupus, and PRV-101 for the prevention of acute coxsackie virus B (CVB), and the prevention of type 1 diabetes (T1D) onset. The company was founded by Francisco Leon and Ashleigh Palmer on October 4, 2016 and is headquartered in Red Bank, NJ. | Health Technology |
- Stock Market
- Insiders
- Mark Rigby
